Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellect Biotechnology Ltd. (NASDAQ: APOP).

Full DD Report for APOP

You must become a subscriber to view this report.


Recent News from (NASDAQ: APOP)

Cellect Receives Multiple Patent Grants
TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of novel stem cell production technology, announced today that it has received a formal Notice of Allowance from the Japanese and Australian Offices for Patents & Trademarks (Japan...
Source: PR Newswire
Date: November, 05 2018 07:00
Cellect to Present Its Breakthrough Stem Cell Production Technology at the BIO-Europe
TEL AVIV, Israel , Nov. 1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP) , a developer of a novel stem cell production technology, announced today its CEO Dr. Shai Yarkoni will present at the 24 th Annual Bio Europe Conference  which is being held in Copenha...
Source: PR Newswire
Date: November, 01 2018 07:00
Cellect Receives Notice of Allowance for Stem Cell Selection Technology Patent in Korea
TEL AVIV, Israel , Aug. 20, 2018 /PRNewswire/ --   Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production technology, announced today it has received a Notice of Allowance from the Korean Intellectual Property Office for its patent titled, "Devic...
Source: PR Newswire
Date: August, 20 2018 07:00
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The ...
Source: SeekingAlpha
Date: August, 14 2018 08:58
Cellect Bio teams up with Cell2in to improve stem cell quality
Cellect Biotechnology Ltd. (NASDAQ: APOP ) will collaborate with South Korea's Cell2in on improving the quality of stem cells. The partnership will leverage Cellect's ApoGraft platform with Cell2in's proprietary stem cell identification technology called FreSHtracer which uses a fluorescen...
Source: SeekingAlpha
Date: August, 13 2018 07:30
Cellect and Cell2in Launch Collaboration to Significantly Improve Stem Cell Selection and Expansion
TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ --  Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of a novel stem cell production technology, announced today that it has signed a collaboration agreement with Cell2in , a South Korean company focused on improving the quality o...
Source: PR Newswire
Date: August, 13 2018 07:00
Cellect Biotechnology Provides Corporate Update and Reports Second Quarter 2018 Financial Results
TEL AVIV, Israel , Aug. 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the second quarter ended June 3...
Source: PR Newswire
Date: August, 09 2018 16:15
Cellect Granted Key European Patent for Its Stem Cell Selection Technology
TEL AVIV, Israel , Aug. 7, 2018  /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today the European Patent Office has granted the company a patent for its platform ApoGraft™ technology and ApoT...
Source: PR Newswire
Date: August, 07 2018 07:00
Cellect Signed Strategic Agreement with Swiss Biotech Center (SBC)
TEL AVIV, Israel, July 9, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced that it has entered into a strategic manufacturing and supply agreement with Swiss Biotech Center (SBC) to secur...
Source: PR Newswire
Date: July, 09 2018 07:00
Cellect Bio and denovoMATRIX team up to develop regenerative medicine product
Cellect Biotechnology (NASDAQ: APOP ) inks a collaboration and material transfer agreement with Technische Universität Dresden's denovoMATRIX group aimed at exploring the potential synergy between Cellect's ApoGraft and denovoMATRIX's technology in regenerative medicine. More news o...
Source: SeekingAlpha
Date: July, 05 2018 07:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-143.052.833.102.7518,389
2018-12-133.16273.083.283.089,178
2018-12-123.153.293.303.1413,389
2018-12-113.203.103.23833.0315,925
2018-12-103.193.193.233.16014,855

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-142,7044,68257.7531Short
2018-12-132,5502,75092.7273Short
2018-12-123,23210,75830.0428Cover
2018-12-111,30015,4508.4142Cover
2018-12-102622,21211.8445Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APOP.


About Cellect Biotechnology Ltd. (NASDAQ: APOP)

Logo for Cellect Biotechnology Ltd. (NASDAQ: APOP)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (NASDAQ: APOP)

    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 17 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: May, 17 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 10 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: April, 09 2018
    Notice from the SEC of registration effectiveness
    Filing Type: EFFECTFiling Source: edgar
    Filing Date: April, 06 2018
    Post-effective amendment to an S-Type filing
    Filing Type: POS AMFiling Source: edgar
    Filing Date: March, 21 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: March, 19 2018
    Annual and transition report of foreign private issuers under sections 13 or 15(d)
    Filing Type: 20-FFiling Source: edgar
    Filing Date: March, 19 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 20 2018
    Prospectus filed under Rule 424(b)(3)
    Filing Type: 424B3Filing Source: edgar
    Filing Date: February, 09 2018

     

     


    Daily Technical Chart for (NASDAQ: APOP)

    Daily Technical Chart for (NASDAQ: APOP)


    Stay tuned for daily updates and more on (NASDAQ: APOP)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: APOP)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APOP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of APOP and does not buy, sell, or trade any shares of APOP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/